Specific Cross-reaction of IgG Anti-phospholipid Antibody with Platelet Glycoprotein IIIa

Shigeru Tokita; Morio Arai; Naomasa Yamamoto; Yasuhiro Katagiri; Kenjiro Tanoue; Koji Igarashi; Masato Umeda; Keizo Inoue

doi:10.1055/s-0038-1650238

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1996; 75(01): 168-174
DOI: 10.1055/s-0038-1650238

Original Article

Schattauer GmbH Stuttgart

Specific Cross-reaction of IgG Anti-phospholipid Antibody with Platelet Glycoprotein IIIa

Shigeru Tokita

¹The Department of Health Chemistry, Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

⁴The Department of Inflammation Research, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

,

Morio Arai

³The Department of Clinical Pathology, Tokyo Medical College, Tokyo, Japan

,

Naomasa Yamamoto

²The Department of Cardiovascular Research, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

,

Yasuhiro Katagiri

²The Department of Cardiovascular Research, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

,

Kenjiro Tanoue

²The Department of Cardiovascular Research, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

,

Koji Igarashi

⁴The Department of Inflammation Research, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

,

Masato Umeda

⁴The Department of Inflammation Research, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

,

Keizo Inoue

¹The Department of Health Chemistry, Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

› Author Affiliations

Abstract

PDF Download

Summary

To study the pathological functions of anti-phospholipid (anti-PL) antibodies, we have analyzed their effect on platelet function. We identified an IgG anti-PL mAb, designated PSG3, which cross-reacted specifically with glycoprotein (GP) IIIa in human platelets and inhibited platelet aggregation. PSG3 bound also to certain polyanionic substances, such as double-stranded DNA, heparan sulfate, dextran sulfate and acetylated-LDL, but not to other polyanionic substances. The binding of PSG3 to GPIIIa was completely inhibited by heparan sulfate and dextran sulfate, indicating that PSG3 recognizes a particular array of negative charges expressed on both GPIIIa and the specified polyanionic substances. Since neither neuraminidase- nor endoglycopeptidase F-treatment of GPIIIa had any significant effect on the binding of PSG3, this array must be located within the amino acid sequence of GPIIIa but not in the carbohydrate moiety. Reduction of the disulfide bonds in GPIIIa greatly reduced its reactivity, suggesting that the negative charges in the epitope are arranged in a particular conformation. PSG3 inhibited platelet aggregation induced by either ADP or collagen, it also inhibited fibrinogen binding to activated platelets in a dose-dependent fashion. PSG3, however, did not inhibit the binding of GRGDSP peptide to activated platelets. These results suggest that the PSG3 epitope on GPIIIa contains a particular array of negative charges, and possibly affects the fibrinogen binding to GPIIb/IIIa complex necessary for platelet aggregation.

PDF (1755 kb)

References

References
1 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein (apoprotein H). Pro Natl Acad Sci USA 1990; 87: 4120-4124
2 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, Yasuda T, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticar-diolipin cofactor. J Immunol 1992; 148: 3885-3891
3 Bevers EM, Galli M, Comfurius P, Zwaal RFA. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
4 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-2625
5 Rauch J, Meng QH, Tannenbaum H. Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies. J Immunol 1987; 139: 2598-2604
6 Meng QH, Rauch J. Differences between human hybridoma platelet-binding antibodies derived from systemic lupus erythematosus patients and normal individuals. Autoimmunity 1990; 5: 151-167
7 Denomme GA, Kelton JG, Bell DA. The production of human monoclonal antiplatelet autoantibodies derived from human lymphocytes of normal origin: reactivity to DNA, anionic phospholipids and platelet proteins. Br J Haematol 1992; 81: 099-106
8 Harris EN, Asherson RA, Hughes GRV. Antiphospholipid antibodies - autoantibodies with a difference. Annu Rev Med 1988; 39: 261-271
9 Alving CR. Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids 1986; 40: 303-314
10 Janoff A, Rauch J. The structural specificity of antiphospholipid antibodies in autoimmune disease. ibid 1986; 315-332
11 Mackworth-Yong C. Antiphospholipid antibodies: more than just a disease marker?. Immunol Today 1990; 11: 60-65
12 McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Advan Immunol 1991; 49: 193-280
13 Umeda M, Igarashi K, Nam KS, Inoue K. Effective production of monoclonal antibodies against phosphatidylserine: stereo-specific recognition of phosphati-dylserine by monoclonal antibody. J Immunol 1989; 143: 2273-2279
14 Igarashi K, Umeda M, Tokita S, Nam KS, Inoue K. Effective production of antiphospholipid and anticoagulant antibodies in normal mouse. Thromb Res 1991; 61: 135-148
15 Clavete JJ. Clues for understanding the structure and function of a prototypic humanintegrin: The platelet glycoprotein II/IIIa complex. Thromb Haemost 1994; 72: 01-15
16 D’Souza S, Ginsberg MH, Burke TA, Lam SC-T, Plow EF. Localization of an Arg-Gly-Asp recognition site with an integrin adhesion receptor. Science 1988; 242: 91-93
17 D’Souza S, Ginsberg MH, Burke TA, Plow EF. The ligand binding site of the platelet integrin receptor GPIIb/IIIa is proximal to the second calcium binding domain of its a subunit. J Biol Chem 1990; 265: 3440-3446
18 Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM. Inhibition of fibrinogen binding to GPIIb/IIIa by a GPIIIa peptide. J Biol Chem 1991; 266: 1415-1421
19 Clavete JJ, Schafer W, Mann K, Henschen A, Gonzalez Rodriguez. Localization of the cross-linking sites of RGD and KQAGDV peptides to the isolated fibrinogen receptor, the human platelet integrin glycoprotein IIb/IIIa. Eur J Biol 1992; 206: 759-765
20 Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-1562
21 Fitzgerald LA, Steiner B, Rail Jr SC, Lo SS, Phillips DR. Protein sequence of endothelial glycoprotein Ilia derived from a cDNA clone. J Biol Chem 1987; 262: 3936-3939
22 Yamamoto N, Kitagawa H, Yamamoto K, Tanoue K, Yamazaki H. Calcium ions and the conformation of glycoprotein IIIa that is essential for fibrinogen binding to platelets: analysis by a new monoclonal anti-GPIIIa antibody, TM83. Blood 1989; 73: 1552-1560
23 Kawashima H, Tomaru A, Yamamoto K, Tuji T, Osawa T. Monoclonal antibodies against human membrane glycoprotein IIIa and collagen-induced platelet activation. Chem Pharm Bull 1989; 37: 397-403
24 Du X, Plow EF, Frelinger III AL, O’Toole TE, Loftus JC, Ginsberg MH. Ligands “activate” integrin α_IIbβ₃ (platelet GPIIb-IIIa). Cell 1991; 5: 409-416
25 Beer JH, Springer T, Coller BS. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein Ilb/IIIa receptor. Blood 1992; 79: 117-128
26 Tanoue K, Akamatsu N, Katagiri Y, Fujimoto T, Kurosawa T, Iwasa S, Koike M, Kawasaki H, Suzuki K, Yamazaki H. Detection of in vivo activated platelets in cerebral thrombosis: studies using a new monoclonal antibody 2T60, specific for activated human and rabbit platelets. Platelets 1993; 4: 31-39
27 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspension of washed platelets from humans. Br J Haematol 1972; 22: 193-204
28 Kim DK, Kudo I, Inoue K. Purification and characterization of rabbit platelet cytosolic phospholipase A₂ . Biochem Biophys Acta 1991; 1083: 80-88
29 Arai M, Yamamoto N, Moroi M, Akamatsu N, Fukutake K, Tanoue K. Platelet with 10% the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol 1995; 89: 124-130
30 Aoki J, Umeda M, Takio K, Titani K, Utsumi H, Sasaki M, Inoue K. Neural cell adhesion molecule mediates contact-dependent inhibition of growth of neardiploid mouse fibroblast cell line m5S/lM. J Cell Biol 1991; 115: 1751-1761
31 Plow EF, Ginsberg MH. Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem 1981; 256: 9477-9482
32 Bolton AE, Hunter WM. Radioimmunoassay and related methods. In: Handbook of Experimental Immunology, vol 1 (ed 4) Weir DM. (ed) Oxford; England: 1986. p 2
33 Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophage that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1987; 76: 333
34 Tsunehisa S, Tuji T, Tohyama H, Osawa T. Interaction of human platelet membrane glycoproteins with collagen and lectins. Biochem Biophys Acta 1984; 797: 10-19
35 Kehrel B, Kokott R, Balleisen L, Stenzinger W, Clemetson KJ, van de Loo J. Selective staining of platelet glycoproteins using two-dimensional O’Farrell gel electrophoresis and avidin-biotin-conjugated lectins. Thromb Haemost 1987; 58: 960-963
36 Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Ann Review Biochem 1983; 52: 223-261
37 Nishikawa K, Arai H, Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophage. 1990; 265: 5226-5231
38 Doolittle RF, Watt KWK, Cottrell BA, Strong DD, Riley M. The amino acid sequence of the a-chain of human fibrinogen. Nature 1979; 280: 464-468
39 Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the y chain. Biochemistry 1984; 23: 1767-1774
40 Umeda M, Igarashi K, Tokita S, Farooq Reza, Inoue K. Anti-phosphatidylserine monoclonal antibody: Structural template for studying lipid-protein interactions and for identification of phosphatidylserine binding proteins. NATO ASI series 1993; H 70: 219-234
41 Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in native mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069-3073
42 Murakami M, Lam Z, Furie BC, Reinhol VN, Asano T, Furie B. Sulfated glycolipids are the platelet autoantigens for human platelet binding monoclonal antiDNA autoantibodies. J Biol Chem 1991; 266: 1541-1549
43 Schwartz RS, Stollar D. Origins of anti-DNA autoantibodies. J Clin Invest 1985; 75: 321-327
44 Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1994; 71: 571-575
45 Fabris F, Steffan A, Cordiano I, Borzini P, Luzzatto G, Randi ML, Girolami A. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994; 53: 232-236
46 Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 1994; 88: 878-880
47 Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Olivieri M, Zaccari G, Gandolfo GM, Galli M, Barbui T, Papat G. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84: 4203-4208